Sugi Predict

Sugi Predict / Compounds / SCHEMBL148335

SCHEMBL148335

SCHEMBL148335

Nc1cc(F)cc(F)c1C(=O)O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KEAP1 Q14145 1/20 0.44
▸ ERN1 O75460 1/20 0.41
▸ CES2 O00748 4/20 0.39
▸ CES1 P23141 4/20 0.39
▸ HDAC1 Q13547 3/20 0.39
▸ ALDH1A1 P00352 3/20 0.38
▸ HCAR1 Q9BXC0 1/20 0.38
▸ KDM4E B2RXH2 4/20 0.35
▸ HSD17B10 Q99714 3/20 0.35
▸ HPGD P15428 2/20 0.35
▸ PDPK1 O15530 1/20 0.35
▸ LMNA P02545 1/20 0.35
▸ TSHR P16473 1/20 0.35
▸ NFKB1 P19838 1/20 0.35
▸ APEX1 P27695 1/20 0.35
▸ CYP2C19 P33261 1/20 0.35
▸ TDP1 Q9NUW8 1/20 0.35
▸ PLK1 P53350 1/20 0.34
▸ PLK3 Q9H4B4 1/20 0.34
▸ KMT2A Q03164 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL288979 0.84 CES2 (0.46) KEAP1ERN1CES2CES1ALDH1A1
SCHEMBL147636 0.83 CES2 (0.39) KEAP1ERN1CES2CES1HDAC1
SCHEMBL29154306 0.81 CES2 (0.44) KEAP1ERN1CES2CES1ALDH1A1
SCHEMBL21750061 0.81 KEAP1 (0.57) KEAP1CES2CES1ALDH1A1HCAR1
SCHEMBL21178071 0.81 CES2 (0.38) KEAP1ERN1CES2CES1HDAC1
SCHEMBL29921597 0.81 CES2 (0.38) KEAP1ERN1CES2CES1HDAC1
SCHEMBL7457291 0.80 HTT (0.38) ERN1CES2CES1HDAC1ALDH1A1
SCHEMBL20552081 0.79 KDM4E (0.46) KEAP1HDAC1ALDH1A1HCAR1KDM4E
SCHEMBL2039681 0.79 KDM4E (0.41) KEAP1HDAC1ALDH1A1KDM4EHSD17B10
SCHEMBL1398086 0.79 CYP3A4 (0.50) KEAP1ALDH1A1HCAR1KDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 164 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2016071485-A1 METHOD FOR DETERMINING THE COMPOSITION OF THE SUGAR MOIETY OF A SUGAR CONTAINING COMPOUND DANMARKS TEKNISKE UNIVERSITET (DK) 2016-05-12 — — WO claimed
US-20260125362-A1 TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY ABBVIE BIOTECHNOLOGY LTD (BM) 2026-05-07 — — US disclosed
EP-4658638-A1 SMALL MOLECULES FOR THE TREATMENT OF MYCOBACTERIAL DISEASES Council of Scientific and Industrial Research, an Indian Registered Body Incorporated under Regn. of Soc. Act (Act XXI of 1860) (IN) 2025-12-10 — — EP disclosed
US-20250361236-A9 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES INC (US) 2025-11-27 — — US disclosed
US-20250171452-A1 TRYPTANTHRIN DERIVATIVES AND USES THEREOF VISCIENT BIO, INC. 2025-05-29 — — US disclosed
EP-4514804-A1 TRYPTANTHRIN DERIVATIVES AND USES THEREOF Viscient Bio, Inc. (US) 2025-03-05 — — EP disclosed
CN-119487031-A Tryptanthrin derivatives and uses thereof 威森特生物公司 2025-02-18 — — CN disclosed
US-20240400568-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2024-12-05 — — US disclosed
CN-114040911-B As NAV1.8 2, 3-Dihydro-quinazoline Compounds as inhibitors 葛兰素史密斯克莱知识产权发展有限公司 2024-10-22 — — CN disclosed
EP-4445902-A2 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS Carna Biosciences, Inc. (JP) 2024-10-16 — — EP disclosed
US-20040214841-A1 Quinazoline derivatives for treatment of tumours ASTRAZENECA AB (SE) 2004-10-28 — — US disclosed
EP-1450808-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF T CELL MEDIATED DISEASES Astrazeneca AB (SE) 2004-09-01 — — EP disclosed
EP-1444211-A2 QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS AstraZeneca AB (SE) 2004-08-11 — — EP disclosed
CN-1434821-A Quinazoline derivatives for the treatment of tumours ASTRAZENECA AB (SE) 2003-08-06 — — CN disclosed
WO-2003045395-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF T CELL MEDIATED DISEASES ASTRAZENECA AB (SE) 2003-06-05 — — WO disclosed
WO-2003040109-A2 QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS ASTRAZENECA AB (SE) 2003-05-15 — — WO disclosed
WO-2001094341-A9 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF TUMOURS ASTRAZENECA AB (SE) 2003-04-17 — — WO disclosed
EP-1292594-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF TUMOURS AstraZeneca AB (SE) 2003-03-19 — — EP disclosed
US-20030004150-A1 New analogues of camptothecin, their use as medicaments and the pharmaceutical compositions containing them IPSEN PHARMA S.A.S. (FR) 2003-01-02 — — US disclosed
WO-2001094341-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF TUMOURS ASTRAZENECA AB (SE) 2001-12-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240400568-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS DGKG, DGKB, DGKK KEAP1 2520/4885ERN1 281/4885CES2 2158/4885
US-20250171452-A1 TRYPTANTHRIN DERIVATIVES AND USES THEREOF IDO2, IDO1, TPSB2 KEAP1 1338/4885ERN1 4774/4885CES2 2805/4885
US-20030004150-A1 New analogues of camptothecin, their use as medicaments and the pharmaceutical compositions containing them TOP1, TOP2A, TYMP KEAP1 3157/4885ERN1 2161/4885CES2 1631/4885
US-20250361236-A9 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS DGKG, DGKB, DGKK KEAP1 2520/4885ERN1 281/4885CES2 2158/4885
US-20040214841-A1 Quinazoline derivatives for treatment of tumours NQO2, TOP1, TPD52L2 KEAP1 974/4885ERN1 3557/4885CES2 2840/4885
US-20260125362-A1 TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY PARP14, PARP16, PARP11 KEAP1 381/4885ERN1 883/4885CES2 3454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.